The drug also showed a manageable safety profile, with just 6.4% of patients stopping treatment due to side effects. No new safety concerns emerged
ILUMYA has already earned FDA approvals for scalp and nail plaque psoriasis in April 2024 and December 2025
The company announced positive topline data from the Phase 3 ADorable-1 trial
At the center of the announcement are two late-breaking studies that could reshape treatment approaches for patients with high cholesterol and a complex form of heart failure
FGFR alterations are prevalent in early-stage bladder cancer, appearing in roughly 70% of intermediate-risk and 40% of high-risk NMIBC tumors
The new entity will operate with separate resources, funding, and operations, while BioNTech will contribute related rights and mRNA technologies to support its ambitious mission
Neupharma gains exclusive rights to develop and commercialize corticorelin for peritumoral brain edema
Salanersen was generally well-tolerated, slowed neurodegeneration, and enabled functional gains
The study hit its primary goal, showing a statistically significant rise in participants achieving EASI-75
The FDA decision was based on results from the pivotal POETYK PsA-1 and POETYK PsA-2 Phase 3 trials
Subscribe To Our Newsletter & Stay Updated
